Menu

Continued Fallout from Macchiarini Misconduct

The sacked researcher and surgeon was not properly vetted by the Swedish institutions that hired him in 2010, according to an independent review panel. 

Sep 7, 2016
Bob Grant

PIXABAY, DEBORABALVESThe swath of destruction caused by the alleged misconduct and fraud of surgeon Paolo Macchiarini continues to widen, as an independent panel reviews his case. In a report released last week (August 31), investigators commissioned by the Karolinska University Hospital—where Macchiarini used to work—stated that both the hospital and the Karolinska Institute (KI) failed to heed warning signs that the artificial organ researcher’s skill and professionalism was not up to par with the reputation he had cultivated in the popular press.

“Macchiarini was recruited as a senior physician at the hospital even though there were strongly critical opinions from his previous employers,” the investigators wrote. “Group thinking, bandwagon effects, a very competitive care environment, many informal leaders and deficient knowledge of and respect for rules are some of the factors that may have contributed to the course of events.”

Two KI officials are suffering backlash from the Macchiarini case. Anders Hamsten, who had already resigned from the institute’s vice-chancellor position over his role in hiring Macchiarini, and Harriet Wallberg, who was president of KI when the surgeon was hired, were both dismissed from the panel that awards Nobel Prizes for Medicine, according to The Guardian. In addition, Wallberg was fired from her post as the chancellor of the Swedish Higher Education Authority on Monday (Sept 5).

Several investigations have probed the Macchiarini case, which involved three artificial trachea implantations he performed while at KI. The researcher’s employment was terminated by the hospital in late 2013, and KI followed suit in March of this year. The most recent investigation echoed allegations of misconduct, including Macchiarini’s apparent failure to secure appropriate and informed consent, provide for his patient’s safety, or obtain necessary ethical clearance for the operations. Macchiarini has maintaned his innocence throughout.

July 2019

On Target

Researchers strive to make individualized medicine a reality

Marketplace

Sponsored Product Updates

Overcoming the Efficiency Challenge in Clinical NGS
Overcoming the Efficiency Challenge in Clinical NGS
Download this white paper to see how an ECS lab serving a network of more than 10,000 healthcare providers integrated QIAGEN Clinical Insight (QCI) Interpret to significantly reduce manual variant curation efforts and increase workflow efficiency by 80%!
Veravas Launches Product Portfolio to Mitigate Biotin Interference and Improve Diagnostic Assay Accuracy
Veravas Launches Product Portfolio to Mitigate Biotin Interference and Improve Diagnostic Assay Accuracy
Veravas, Inc., an emerging diagnostic company, launched a portfolio of products that can improve the accuracy of current diagnostic test results by helping laboratory professionals detect and manage biotin interference in patient samples with VeraTest Biotin and VeraPrep Biotin.
New Data on Circulating Tumor DNA as a Biomarker for Detecting Cancer Progression Presented at 2019 ASCO Annual Meeting
New Data on Circulating Tumor DNA as a Biomarker for Detecting Cancer Progression Presented at 2019 ASCO Annual Meeting
Scientists presented more than 30 abstracts featuring Bio-Rad’s Droplet Digital PCR (ddPCR) technology at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, May 31–June 4.
BellBrook Labs Receives NIH Grant for the Discovery of cGAS Inhibitors to Treat Autoimmune Diseases
BellBrook Labs Receives NIH Grant for the Discovery of cGAS Inhibitors to Treat Autoimmune Diseases
The National Institute Of Allergy And Infectious Disease recently awarded BellBrook Labs a $300,000 Small Business Innovative Research (SBIR) grant to develop novel inhibitors for the target cyclic GAMP Synthase (cGAS). The grant will be used to accelerate the discovery of new treatments for autoimmune diseases by targeting the cGAS-STING pathway.